{"entity":{"id":"nct05775159","kind":"trial","name":"Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer","aka":["GEMINI-Hepatobiliary"],"tldr":"A phase 2 trial of Bevacizumab, Lenvatinib, Rilvegostomig in hepatocellular carcinoma, run by AstraZeneca, active and no longer recruiting.","summary":"Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer is a phase 2 interventional study registered as NCT05775159 by AstraZeneca, with 294 participants planned, started 2023-04-24 and due to reach its primary completion in 2026-10-27. Interventions recorded: Volrustomig, Bevacizumab, Lenvatinib, Rilvegostomig, Gemcitabine. Conditions listed: Hepatocellular Carcinoma, Biliary Tract Cancer. No results are recorded here; the registry entry is the source.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05775159","url":"https://clinicaltrials.gov/study/NCT05775159"}],"tags":["ctgov-ingest"],"related":[],"cancers":["hcc"],"sections":[],"technologies":[],"targets":[],"drugs":["bevacizumab","lenvatinib","rilvegostomig","gemcitabine","cisplatin"],"companies":["astrazeneca"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05775159","phase":"2","setting":"A Phase II, Open-Label, Multi-Drug, Multi-Center, Master Protocol to Evaluate the Efficacy and Safety of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer (GEMINI-Hepatobiliary)","sponsor":"AstraZeneca","participation":[{"nct":"NCT05775159","source":"https://clinicaltrials.gov/study/NCT05775159","fetchedAt":"2026-10-07T16:53:55.392Z","studySha256":"230da38672e97658f4ccdb8376bf32601b41f7eee74ae242763d7f05fb3f8348","overallStatus":"ACTIVE_NOT_RECRUITING","lastUpdatePosted":"2026-08-24","leadSponsor":"AstraZeneca","collaboratorCount":0,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":294,"enrolmentType":"ESTIMATED","siteCount":46,"recruitingSiteCount":0,"countries":["China","Hong Kong","Italy","Japan","South Korea","Spain","Taiwan","United Kingdom","United States"]}],"started":"2023-04-24","startedType":"actual","enrolled":294,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05775159/","neighbours":{"cancer":[{"id":"hcc","kind":"cancer","name":"Hepatocellular carcinoma","route":"/cancers/hcc/"}],"drug":[{"id":"bevacizumab","kind":"drug","name":"Bevacizumab","route":"/drugs/bevacizumab/"},{"id":"cisplatin","kind":"drug","name":"Cisplatin","route":"/drugs/cisplatin/"},{"id":"gemcitabine","kind":"drug","name":"Gemcitabine","route":"/drugs/gemcitabine/"},{"id":"lenvatinib","kind":"drug","name":"Lenvatinib","route":"/drugs/lenvatinib/"},{"id":"rilvegostomig","kind":"drug","name":"Rilvegostomig","route":"/drugs/rilvegostomig/"}],"company":[{"id":"astrazeneca","kind":"company","name":"AstraZeneca","route":"/companies/astrazeneca/"}]}}